AUS
NZ
UK
CA
USA
IND
Highlights
- TSS (OTC:TSSI) holds stronger profitability metrics than Pharma-Bio Serv (OTC:PBSV).
- Pharma-Bio Serv demonstrates a more accessible valuation with a lower price-to-earnings ratio.
- Beta values reveal that Pharma-Bio Serv has a lower market fluctuation level than TSS.
The compliance and technology consulting segment, along with specialized facility services, represents an important portion of the broader life sciences and data center infrastructure fields. Companies such as Pharma-Bio Serv (OTC:PBSV) and TSS (OTC:TSSI) occupy positions in this space, offering solutions ranging from regulatory compliance to robust engineering strategies.
Profitability Metrics
Based on recent figures, TSS exhibits stronger results in core profitability categories. TSS shows a net margin of approximately three percent, coupled with a return on equity of over eighty percent and a return on assets of around eleven percent. Pharma-Bio Serv displays negative readings in these areas, with a net margin of less than zero percent, a return on equity near negative six percent, and a return on assets near negative four percent. These figures present a clear separation in overall profitability, with TSS reflecting a higher capacity to generate income relative to expenses and assets.
Revenue and Valuation
TSS records higher top-line results by bringing in revenue that exceeds one hundred million dollars, and the earnings per share figure stands around zero point one eight. Pharma-Bio Serv’s revenue remains below ten million dollars, with an earnings per share statistic of negative zero point zero three. Although TSS posts stronger earnings, its price-to-earnings metric hovers in the sixties, while Pharma-Bio Serv trades around negative twenty. These details point to a distinct difference in perceived worth, as TSS carries a premium, whereas Pharma-Bio Serv trades at a comparatively lower multiple.
Market Volatility
In terms of broader market movements, Pharma-Bio Serv carries a beta around zero point five, suggesting that its share price may experience smaller shifts compared to the overall market. TSS maintains a beta near zero point eight, indicating slightly reduced movement relative to standard market fluctuations but higher than Pharma-Bio Serv’s figure. This contrast in beta underscores varying levels of share price swings between the two entities.
Business Operations
Pharma-Bio Serv functions as a compliance and technology consulting entity, established in the early nineteen nineties with headquarters in Dorado, Puerto Rico. Its services span areas such as regulatory compliance, engineering, and project management, primarily targeting industries that include pharmaceuticals and biotechnology. TSS, formerly operating under a different name, is based in Columbia in the United States and focuses on specialized facility services, including planning, design, and engineering for critical environments like data centers and medical facilities. This approach aligns with its emphasis on developing and managing high-reliability infrastructure.
